Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$88.85 USD

88.85
926,404

-0.15 (-0.17%)

Updated Oct 28, 2024 12:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Incyte, Foundation Medicine Partner for Companion Diagnostics

Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.

    Endocyte Announces FDA's Acceptance of Trial Endpoint Change

    177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients

      Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

      Gilead Sciences (GILD) closed the most recent trading day at $72.51, moving +0.36% from the previous trading session.

        Shire's ADHD Portfolio Remains Strong Amid Competition

        Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.

          Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

          Inovio (INO) focuses on the development of its most advanced candidate, VGX-3100 vaccine, which has been progressing well. Its collaboration with big pharma companies exhibits strong growth.

            The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE

            The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE

              Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine

              Inovio Pharmaceuticals (INO) administers dosage in the first patient under a phase I/IIa trial to assess its MERS vaccine INO-4700.

                Mark Vickery headshot

                Top Research Reports for Abbott, Gilead & FedEx

                Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Gilead (GILD) and FedEx (FDX).

                  bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy

                  bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.

                    Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint

                    Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.

                      ProQR Up More Than 120% on Favorable Eye Disorder Study Data

                      ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

                        Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx

                        Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

                          Horizon Pharma Completes Enrollment in Eye Disease Study

                          Horizon Pharma (HZNP) completes early enrollment for the confirmatory phase III study of teprotumumab, which is being evaluated for the treatment of thyroid eye disease.

                            Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout

                            Bayer (BAYRY) misses earnings estimates in the second quarter of 2018. The company completes the acquisition of Monsanto for $63 billion.

                              MannKind Stock Up on Licensing Deal With United Therapeutics

                              MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.

                                Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals

                                Shares of Alnylam (ALNY) increase due to the FDA and European approval for Onpattro.

                                  Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)

                                  Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

                                    Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine

                                    Inovio Pharmaceuticals (INO) and Korean partner GeneOne Life Science dose the first patient in a phase I study, which will assess its hepatitis C vaccine GLS-6150.

                                      AstraZeneca's Lupus Drug Misses Primary Endpoint in Study

                                      AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.

                                        Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A

                                        Bayer's (BAYRY) Jivi gets FDA approval for the treatment of hemophilia A in previously-treated adults and adolescents aged 12 years and older.

                                          Alnylam Gets European Nod for First-Ever RNAi Therapeutic

                                          Alnylam's (ALNY) Onpattro, the first ever RNA interference (RNAi) therapeutic, has been granted marketing authorization by the European Commission.

                                            Merck (MRK) Receives FDA Approval for Two HIV Medicines

                                            Merck's (MRK) two new HIV-1 medicines, Delstrigo and Pifeltro, get approval in the United States.

                                              Bristol-Myers' Sprycel Seeks Label Expansion in the U.S.

                                              The FDA accepts Bristol-Myers' (BMY) sBLA for label expansion of Sprycel for the treatment of pediatric patients with newly diagnosed Ph+ ALL.

                                                Glaxo's Asthma Drug Gets EU Nod for Pediatric Population

                                                Glaxo (GSK) gains EU approval for asthma drug Nucala as an add-on treatment for severe refractory eosinophilic asthma in children.

                                                  Vertex Inks Deal With Genomics to Make Serious Disease Drugs

                                                  Vertex (VRTX) signs a three-year collaboration contract with Genomics to develop novel drug targets for advancing discovery of precision medicines.